Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alnylam Pharmaceuticals, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ALNY
Nasdaq
2830
www.alnylam.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alnylam Pharmaceuticals, Inc.
Alnylam vs. Ionis: Here's the Better Bad-News Buy
- Oct 10th, 2026 3:04 am
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
- Oct 9th, 2026 10:55 am
Is Vertex Stock Worth More Than Its Competitors?
- Oct 9th, 2026 9:36 am
Alnylam Pharmaceuticals (ALNY) Stock Looks Pricey Despite A 51% Slide
- Oct 9th, 2026 9:11 am
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
- Oct 9th, 2026 8:53 am
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
- Oct 9th, 2026 7:37 am
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
- Oct 9th, 2026 6:31 am
Alnylam Pharmaceuticals (ALNY) Looks Undervalued On Paper, Can Its RNAi Pipeline Support Fair Value?
- Oct 8th, 2026 12:08 pm
Here's Why You Should Add LPCN Stock to Your Portfolio Now
- Oct 8th, 2026 7:57 am
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
- Oct 8th, 2026 7:49 am
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
- Oct 7th, 2026 9:08 am
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
- Oct 6th, 2026 7:30 am
3 Great Healthcare Stocks To Own In October 2026
- Oct 2nd, 2026 7:12 am
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
- Sep 29th, 2026 7:00 am
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
- Sep 28th, 2026 7:57 am
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
- Sep 28th, 2026 3:43 am
RNAi drug specialist ADARx raises $446M IPO
- Sep 24th, 2026 6:36 pm
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
- Sep 22nd, 2026 11:39 am
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
- Sep 21st, 2026 10:40 am
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
- Sep 20th, 2026 10:02 am
Scroll